CannaMD
NOVEMBER 8, 2019
A 2009 Canadian clinical trial of synthetic cannabinoid medication, nabilone , found: The majority of patients (72%) receiving nabilone experienced either cessation of nightmares or a significant reduction in nightmare intensity. Medical marijuana may also play a role in treating nightmares.
The Cannigma
JANUARY 13, 2023
The ECS touches on nearly every biological function you have, including sleep, pain, appetite, body temperature, immune function, memory, and hormone regulation. 3 A 2009 study touched on the trigeminal system as well, examining the connection between the CB1 gene (called CNR1) and people who reported migraines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
TheAnswerPage
JANUARY 11, 2022
Some patients put faith in anecdotal reports or the encouraging results of observational studies, but anecdotal reports and observational studies are not double blind randomized controlled clinical trials and do not prove that a treatment is or is not effective.
The Cannigma
DECEMBER 12, 2022
It became illegal in the US in 2009. Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. As such, there have been numerous clinical trials using ketamine.
Cannabis Law Report
JUNE 4, 2021
D8 may well assist with relaxation and sleep. The slight “high” seems to be part of the appeal but the relaxation and sleep benefits also carry broad appeal as well. They also sleep better and aren’t as bothered by “Musculo-Skeletal Discomfort”. Do you think there would be such a fuss about 8 if it didn’t get people “high”? .
SMPL
MAY 26, 2020
And though a few outliers responded well to CBD alone, GW’s data showed that for relieving pain and inflammation, helping with sleep and alleviating seizures and spasms, most patients got the most benefit from an equal mix of CBD and THC — a drug the company called Sativex. But the research wasn’t enough.
Cannabis Law Report
JUNE 4, 2021
Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Originally a lawyer, Yang began working in startups and early stage growth companies as a founder or executive from 2000 to 2009.
Expert insights. Personalized for you.
85 
Let's personalize your content